Blog
RSS FeedPosted by Michael Wonder on 30 Nov 2020
Canada to Trump: you can't take our prescription drugs
30 November 2020 - Canada is putting the kibosh on President Donald Trump's efforts to lower drug prices by importing ...
Posted by Michael Wonder on 29 Nov 2020
Canada bans mass exports of prescription drugs
29 November 2020 - Canada has banned the export of some prescription medicines in order to prevent a shortage in ...
Posted by Michael Wonder on 15 Nov 2020
Drug makers offer Canada 1 billion dollars to scrap some pending pricing rules
16 November 2020 - The pharmaceutical industry has made a last-ditch C$1 billion ($761 million) proposal to the Canadian government ...
Posted by Michael Wonder on 10 Nov 2020
Manufacturer moves to bring 'life-changing' cystic fibrosis drugs to Canada
10 November 2020 - A pharmaceutical company says it's taking steps to bring cystic fibrosis drugs to Canada in a ...
Posted by Michael Wonder on 10 Nov 2020
Bausch Health Canada receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Duobrii - a novel topical anti-psoriatic prescription drug
10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 09 Nov 2020
Eligible patients living with rare debilitating genetic disorder are one step closer to having access to first-of-its-kind treatment option
5 November 2020 - Takeda Canada is pleased to announce it has completed the Letter of Intent with the pan Canadian ...
Posted by Michael Wonder on 05 Nov 2020
Alberta, Canada sees early success from switching patients to biosimilars
5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% ...
Posted by Michael Wonder on 01 Nov 2020
CADTH recommends new treatment option for patients with plaque psoriasis
30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...
Posted by Michael Wonder on 01 Nov 2020
John Ivison: The math of saving lives — Canada's drug battle leaves patients caught in the middle
31 October 2020 - By cold mathematics, spending $1.3 billion to transform the lives of 3,700 Canadians might seem a ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 27 Oct 2020
Sales of cancer medicines in Canada nearly tripled over the past decade
27 October 2020 - Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook ...
Posted by Michael Wonder on 27 Oct 2020
Mavenclad (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with relapsing-remitting multiple sclerosis
27 October 2020 - EMD Serono is pleased to announce that eligible patients have access to Mavenclad (cladribine tablets) through ...
Posted by Michael Wonder on 24 Oct 2020
Health Canada releases final version of controversial regulations for controlling drug prices
23 October 2020 - After months of delay, Health Canada has released a final version of new regulations that are ...
Posted by Michael Wonder on 22 Oct 2020
Nexplanon recommended after second submission
22 October 2020 - The first submission was withdrawn. ...
Posted by Michael Wonder on 22 Oct 2020
CADTH in favour of new indication for Soliris
22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...